Singapore, May 24 -- Australian pharmaceutical firm Phebra has continued its international business expansion with the opening of its subsidiary in Montreal, Canada. The new entity, Phebra Canada, will be headed by Tony Romagnino, Vice President of Phebra's current North America operations.

Further, Phebra Canada has announced the marketing approval for Arsenic Trioxide Solution for Injection for Acute Promyelocytic Leukaemia (APL).

"Arsenic Trioxide (ATO) is recognised as a very effective treatment for newly diagnosed APL patients and we are extremely pleased to have received its marketing approval in Canada," Mr Romagnino said.

Chief Executive Officer, Dr Mal Eutick, welcomed the marketing approval for Arsenic Trioxide Solution for I...